Single-cell sequencing in pancreatic cancer research: A deeper understanding of heterogeneity and therapy - 11/11/23
Abstract |
Pancreatic cancer, including pancreatic ductal adenocarcinomas (PDACs), is a malignant tumor with characteristics of tumor-stroma interactions. Patients often have a poor prognosis and a poor long-term survival rate. In recent years, rapidly-developing single-cell sequencing techniques have been used to analyze cell populations at a single-cell resolution, so that it is now possible to have a more in-depth and clearer understanding of the genetic composition of pancreatic cancer. In this review, we provide an overview of the current single-cell sequencing techniques and their applications in the exploration of intratumoral heterogeneity, the tumor microenvironment, therapy resistance, and novel treatments. Our hope is to provide new insight into the potential of precision therapy, which will perhaps one day lead to significant advances in PDAC treatment.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Single-cell sequencing can reveal the pancreatic cancer heterogeneous landscape. |
• | Single-cell sequencing can identify distinct stromal cells and their diverse cell phenotypes and molecular characteristics. |
• | Single-cell sequencing can provide novel insights into resistance mechanism and predict treatment outcomes. |
Abbreviations : ADEX, apCAFs, CAFs, csCAFs, ddMDAdigital, DUSP4, ECM, EMT, eWGA, FACS, FAP, GM-CSF, gMDSCs, HIF, iCAFs, IMCs, IPMN, LCM, LIANTI, MACS, MALBAC, MDA, MDSCs, M-MDSC, myCAFs, NK cells, OGCs, PBMC, PDAC, PDOs, PDX, pEMT, PMN-MDSC, PSCs, RFA, TAMs, TAN, TCR, TIL, TME, TNFRSF4, Tregs, TRM-like cell, TXNIP, UCOGC
Keywords : Single cell sequencing, Pancreatic cancer, Heterogeneity, Tumor microenvironment, Pancreatic cancer therapy
Plan
Vol 168
Article 115664- décembre 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?